Kevin Tracey, a neurosurgeon whose early personal experience with brain cancer inspired his career, has played a pivotal role in advancing research on the vagus nerve and its applications in treating inflammation and autoimmune diseases. Now 68, Tracey's work has helped reshape understanding of the nerve, which connects the brainstem to the abdomen and plays a key role in regulating vital bodily functions such as heart rate and digestion.

Tracing its roots to a tragic moment when a toddler died in his arms, Tracey’s research uncovered how the nervous system interacts with inflammation, a process once thought to be governed solely by the immune system. His team demonstrated that stimulating the vagus nerve electrically could prevent an inflammatory cytokine storm, a dangerous immune response, effectively acting as a "brake pedal" on inflammation.

This discovery paved the way for treatments that regulate immune responses via nerve stimulation rather than solely relying on drugs. In July 2025, the U.S. Food and Drug Administration approved a vagus nerve stimulator implanted in the neck for rheumatoid arthritis, a disease affecting over 1 million Americans and about 1 percent of Israel’s population. The device, developed by SetPoint Medical—a company Tracey co-founded but from which he has since stepped back—offers an alternative to costly medications with serious side effects.

Tracey acknowledges that while some claims about vagus nerve stimulation remain speculative, scientific evidence supports its role in reducing inflammation and improving mood. The nerve’s complexity, with approximately 20,000 fibers transmitting signals predominantly from the body to the brain, has made it a focus of both medical research and alternative therapies. Noninvasive stimulation techniques targeting branches of the nerve in the ear or neck are popular among practitioners and enthusiasts seeking relief from a range of conditions.

At the same time, clinical specialists caution that proper use and placement of stimulation devices are crucial. In Israel, vagus nerve stimulation is approved but not widely covered by public health services, requiring patients to seek special approval. Physicians report mood improvements in epilepsy patients fitted with stimulators, even when seizure reduction is limited. The mechanism may involve influencing neurotransmitter production in the brain, though it remains under investigation.

Complementary to clinical treatments, research into vagus nerve functions is expanding into areas like cancer-related cachexia, a debilitating wasting syndrome affecting many advanced cancer patients. Scientists including Prof. Ayelet Erez at the Weizmann Institute of Science are exploring how nerve signaling contributes to muscle breakdown and weight loss in such conditions, aiming for new therapeutic strategies.

Tracey’s journey from personal tragedy to leading researcher underscores the vagus nerve’s emerging role as a key interface between the nervous and immune systems. His work highlights the potential for nerve-based therapies to complement or reduce reliance on traditional pharmaceuticals, with ongoing research offering hope for improved management of inflammatory diseases and beyond.